In critically ill patients with Covid-19 receiving organ support in ICUs, treatment with the interleukin-6 receptor antagonists tocilizumab and sarilumab improved outcomes, including survival. (REMAP-CAP ClinicalTrials.gov number, NCT02735707.).
Dr. Ana M. Aparicio is a Oncologist in Houston, TX. Find Dr. Aparicio's phone number, address, insurance information, hospital affiliations and more.
Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results. N Engl J Med. 2021 Feb 11;384 (6):497-511. doi: 10.1056/NEJMoa2023184.
Strategies definition, and promotional campaigns. Support in B2C and B2B sales, KPIs, coaching, and training of salespeople. Expertise in business development. One of my most important accounts is ...
Antinuclear antibodies (ANA) refer to an autoantibody directed at material within the nucleus of a cell. ANAs are typically classified into two groups, antibodies to DNA and histones and antibodies to nuclear material. Antibodies to DNA and histones include anti-dsDNA antibodies and anti-histone antibodies.
Dr. Cuervo is co-director of the Einstein Institute for Aging Research, and a member of the Einstein Liver Research Center and Cancer Center. In October 2001 she started her laboratory at Einstein, where she studies the role of protein-degradation in aging and age-related disorders, with emphasis in neurodegeneration and metabolic disorders.
Viral Vaccines. spike protein, SARS-CoV-2. 2019-nCoV Vaccine mRNA-1273. Vaccination of nonhuman primates with mRNA-1273 induced robust SARS-CoV-2 neutralizing activity, rapid protection in the upper and lower airways, and no pathologic changes in the lung.
Environmental surveillance of surface contamination is an unexplored tool for understanding transmission of SARS-CoV-2 in community settings. We conducted longitudinal swab sampling of high-touch non-porous surfaces in a Massachusetts town during a COVID-19 outbreak from April to June 2020. Twenty-n …
Ana M. MORA, Researcher | Cited by 2,126 | of University of California, Berkeley, CA (UCB) | Read 109 publications | Contact Ana M. MORA